NB-PP_1170x120

Impax Laboratories

Amneal and Impax create diversified pharmaceutical company

Amneal and Impax create diversified pharmaceutical company

BRIDGEWATER, N.J. — Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. announced that they have completed their business combination to form Amneal Pharmaceuticals, Inc. As a diversified company with a robust generics business, Amneal is now the 5th largest generics business in the United States, with a growing, high-margin specialty franchise. Shares of Impax  ceased trading

Solodyn generics launched by Teva, Impax

Solodyn generics launched by Teva, Impax

NEW YORK — Teva Pharmaceutical Industries Ltd. and Impax Laboratories Inc. have released minocycline HCl extended-release tablets, an acne medication, in 65 mg and 115 mg dosages. The minocycline products are generic versions of Solodyn (minocycline HCl ER tablets, 65 mg and 115 mg) from Ortho Dermatologics, a unit of Valeant Pharmaceuticals International Inc. Impax’s minocycline product is an authorized generic. An oral antibiotic, minocycline HCl

Perrigo introduces trio of new generics

Perrigo introduces trio of new generics

DUBLIN, Ireland — Perrigo Co. plc this week announced three new generic drug products, including two acne treatments and a menopause medication. Perrigo said Friday that it has received tentative Food and Drug Administration approval for clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel, a generic version of Onexton Gel from Valeant Pharmaceuticals International. Perrigo said it previously

Allergan COO to become Amneal CEO

Allergan COO to become Amneal CEO

NEW YORK — Merger partners Amneal Pharmaceuticals LLC and Impax Laboratories Inc. have tabbed Robert Stewart, executive vice president and chief operating officer of Allergan plc, to lead the combined company. Plans call for Stewart to join Amneal as president effective Jan. 25. After Amneal and Impax finalize their merger, announced in mid-October, he will

Amneal, Impax agree to merge

Amneal, Impax agree to merge

NEW YORK — Amneal Pharmaceuticals LLC and Impax Laboratories Inc. plan to merge in an all-stock transaction. An Amneal-Impax merger would create the fifth-largest generics supplier by gross revenue in the United States. To be named Amneal Pharmaceuticals Inc., the new entity will also possess a growing, high-margin specialty drug franchise. Financial terms of the deal

CVS offers low-cost EpiPen alternative

WOONSOCKET, R.I. — CVS Health is providing a low-cost alternative Mylan’s EpiPen epinephrine auto-injector for anaphylaxis. CVS has made Impax Laboratories’ epinephrine auto-injector available at all CVS Pharmacy drug stores at a cash price of $109.99 for a two-pack. That compares with a cash price of $649.99 for the branded EpiPen and $339.99 for the

CVS serves up low-cost EpiPen option

CVS serves up low-cost EpiPen option

WOONSOCKET, R.I. — In the wake of the public outcry over pricing for Mylan’s EpiPen epinephrine auto-injector for anaphylaxis, CVS Health announced that it’s providing a low-cost alternative. CVS said Thursday that Impax Laboratories’ authorized generic for the Adrenaclick epinephrine auto-injector is now available at all CVS Pharmacy drug stores at a cash price of $109.99

Impax highlights its generic epinephrine auto-injector

Impax highlights its generic epinephrine auto-injector

HAYWARD, Calif. — Impax Laboratories Inc. is spotlighting its generic epinephrine auto-injector amid a public outcry over the cost of emergency medication for anaphylaxis, a potentially life-threatening allergic reaction. In what Impax called an update, the company said it’s providing additional information to patients, doctors and customers about its epinephrine injection auto-injector in 0.15-mg and

Impax to acquire generics from Teva, Allergan

Impax to acquire generics from Teva, Allergan

HAYWARD, Calif. — Impax Laboratories Inc. has agreed to buy a portfolio of generic drug products from Teva Pharmaceutical Industries Ltd. and affiliates of Allergan plc for $586 million. Impax said Tuesday that the purchase — covering solid oral, inhalable, injectable and topical dosage forms — includes a group of 15 currently marketed generic products;

Impax to release Emverm chewable tablets

Impax to release Emverm chewable tablets

HAYWARD, Calif. — Impax Laboratories Inc. has received Food and Drug Administration approval for its supplemental new drug application for Emverm 100-mg chewable tablets, a medication for parasitic worms. Ampex said Friday that Emverm (mebendazole) is indicated for the treatment of pinworm (Enterobius vermicularis), whipworm (Trichuris trichiura), common roundworm (Ascaris lumbricoides), common hookworm (Ancylostoma duodenale)

Impax cleared to market Intuniv generic

Impax cleared to market Intuniv generic

HAYWARD, Calif. — Impax Laboratories Inc. has received approval from the Food and Drug Administration for guanfacine extended-release tablets, a treatment for attention deficit hyperactivity disorder (ADHD). Impax said late Wednesday that its guanfacine ER product, a generic version of Intuniv from Shire, comes in strengths of 1 mg, 2 mg, 3 mg and 4

Impax’s Zomig Nasal Spray OK’d as pediatric migraine treatment

Impax’s Zomig Nasal Spray OK’d as pediatric migraine treatment

HAYWARD, Calif. — Impax Specialty Pharma’s Zomig Nasal Spray has been approved by the Food and Drug Administration for use in children ages 12 and older for the acute treatment of migraine. Parent company Impax Laboratories Inc. said Tuesday that the product  is the first nasal-delivered prescription medicine approved for the treatment of acute migraine